Novel genetic marker in ovarian and lung cancers
from Technology Networks
Two new papers, published simultaneously in Nature Communications and led by researchers at McGill University, offer promise that a drug currently used to treat estrogen positive breast cancer may be effective in treating two different types of cancer, one rare and one common form. The breakthrough discovery launching this research came in 2014 when Dr. William Foulkes, James McGill Professor in the Departments of Medicine, Oncology and Human Genetics at McGill's Faculty of Medicine, showed that small cell carcinoma of the ovary, hypercalcemic type, a rare but highly fatal cancer which primarily strikes younger women, is caused by mutations in the gene SMARCA4.
7701 Las Colinas Blvd., Ste. 800, Irving, TX 75063